Dishman Carbogen Amcis per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹1.03₹6.22₹0.21−₹9.79−₹1.90
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹1.03₹6.22₹0.21−₹9.79−₹1.90
₹425.82₹425.82₹371.91₹358.90₹370.51
₹185.04₹186.98₹172.93₹166.82₹153.89
—₹31.34₹23.93₹24.49₹14.05
₹14.38₹14.38₹10.11₹5.15−₹22.56
15.715.715.715.715.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DCAL₹148.86

Dishman Carbogen Amcis Limited

· Pharma & Health
₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,334 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-1.90-9.790.216.221.03
Diluted EPS-1.90-9.790.216.221.03
Book Value per Share370.51358.90371.91425.82425.82
Revenue per Share153.89166.82172.93186.98185.04
Cash Flow per Share14.0524.4923.9331.34—
Free Cash Flow per Share-22.565.1510.1114.3814.38
Shares Outstanding (cr)15.715.715.715.715.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.